Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243575 | 0.93 | LMNA (0.43) | LMNAGPR183FAAHCYP2C19MMP1 | |
| SCHEMBL1979493 | 0.88 | HPGD (0.49) | — | |
| SCHEMBL1982673 | 0.84 | LMNA (0.50) | LMNAFAAHCYP2C19MMP1MMP7 | |
| SCHEMBL14243776 | 0.80 | NPC1 (0.44) | LMNAIKBKBAURKACHUKFLT3 | |
| SCHEMBL1983279 | 0.77 | LMNA (0.45) | LMNAMMP1MMP7MMP8MMP12 | |
| SCHEMBL2768562 | 0.77 | LMNA (0.50) | LMNAGPR183 | |
| SCHEMBL2475456 | 0.76 | CHRM4 (0.53) | — | |
| SCHEMBL1980008 | 0.75 | HTR1A (0.38) | — | |
| SCHEMBL30728596 | 0.75 | LMNA (0.63) | LMNAGPR183FAAHCYP2C19MMP1 | |
| SCHEMBL16564478 | 0.73 | ALDH1A1 (0.40) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | claimed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | claimed |
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | TYR, DDT, TH | LMNA 4049/4885GPR183 2726/4885FAAH 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.